Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

Autor: Andrés J M, Ferreri, Kate, Cwynarski, Elisa, Pulczynski, Christopher P, Fox, Elisabeth, Schorb, Claudia, Celico, Monica, Falautano, Alessandro, Nonis, Paul, La Rosée, Mascia, Binder, Alberto, Fabbri, Fiorella, Ilariucci, Mauro, Krampera, Alexander, Roth, Claire, Hemmaway, Peter W, Johnson, Kim M, Linton, Tobias, Pukrop, Jettes Sønderskov, Gørløv, Monica, Balzarotti, Georg, Hess, Ulrich, Keller, Stephan, Stilgenbauer, Jense, Panse, Alessandra, Tucci, Lorella, Orsucci, Francesco, Pisani, Manuela, Zanni, Stefan W, Krause, Hans J, Schmoll, Bernd, Hertenstein, Mathias, Rummel, Jeffery, Smith, Lorenz, Thurner, Giuseppina, Cabras, Elsa, Pennese, Maurilio, Ponzoni, Martina, Deckert, Letterio S, Politi, Jurgen, Finke, Antonella, Ferranti, Kelly, Cozens, Elvira, Burger, Nicoletta, Ielmini, Franco, Cavalli, Emanuele, Zucca, Gerald, Illerhaus

Publikováno v: Ferreri, A J M, Cwynarski, K, Pulczynski, E, Fox, C P, Schorb, E, Celico, C, Falautano, M, Nonis, A, La Rosée, P, Binder, M, Fabbri, A, Ilariucci, F, Krampera, M, Roth, A, Hemmaway, C, Johnson, P W, Linton, K M, Pukrop, T, Gørløv, J S, Balzarotti, M, Hess, G, Keller, U, Stilgenbauer, S, Panse, J, Tucci, A, Orsucci, L, Pisani, F, Zanni, M, Krause, S W, Schmoll, H J, Hertenstein, B, Rummel, M, Smith, J, Thurner, L, Cabras, G, Pennese, E, Ponzoni, M, Deckert, M, Politi, L S, Finke, J, Ferranti, A, Cozens, K, Burger, E, Ielmini, N, Cavalli, F, Zucca, E, Illerhaus, G & IELSG32 study investigators 2022, ' Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma : 7-year results of the IELSG32 randomized trial ', Leukemia, vol. 36, no. 7, pp. 1870-1878 . https://doi.org/10.1038/s41375-022-01582-5

219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca71e062cac7ea0aa1bd288b51b3ad3b
https://pubmed.ncbi.nlm.nih.gov/35562406